What scientists mean by endocrine disruptor and what labels mean

A bottle of shampoo says it is free of endocrine disruptors. A sealed can of beans says nothing at all. Which one was tested?

Neither, in the way you are probably picturing. No federal list of endocrine disruptors exists for a product to be checked against, no test exists that a product passes, and no agency certifies the claim.

That is not the same as saying the science behind the words is nonsense. Endocrine disruption is a real field with real findings, a federal screening program, and one genuine argument at its center that has run for roughly thirty years without resolution. Both things are true at once, which is exactly why the subject is hard to read.

This article is not a list of chemicals to avoid. It is the set of distinctions that lets you read the next claim, on a package or in a headline.

Your hormone system runs on very small amounts

Hormones are the body’s chemical messengers. Endocrine glands make them, they travel in the bloodstream to distant tissues, and they work slowly. The National Library of Medicine’s MedlinePlus service names the major glands as the pituitary, pineal, thymus, thyroid, adrenal glands and pancreas, with the testes and ovaries producing hormones too. Between them they govern growth, metabolism, sexual function and mood.

Then MedlinePlus adds the sentence that makes this whole subject difficult: “It takes only a tiny amount to cause big changes in cells or even your whole body.”

That cuts both ways. In a system running on quantities this small, a tiny amount cannot be waved off as automatically meaning no amount worth measuring. That is a reason for careful study. It is not, by itself, evidence that a particular chemical at a particular level is doing anything. Keeping those two statements apart is most of the skill this article is trying to hand you.

Hormones also bind their receptors in a balance, so the number of free receptors matters as much as the amount of free hormone. Identical hormone levels can therefore mean different things in different tissues, and in the same tissue at different points in development. A group of 23 international scientists made that point in a consensus statement published in Archives of Toxicology in 2017.

Three ways to interfere with a hormone

The National Institute of Environmental Health Sciences, in a March 2023 fact sheet, says endocrine-disrupting chemicals come from both natural and manufactured sources, and sorts their behavior under three verbs: mimic, block, interfere. Each is worth unpacking.

Mimicry. A chemical partly resembles a natural hormone, binds the receptor and triggers a response. NIEHS names estrogens, androgens and thyroid hormones as the systems where this shows up, with overstimulation as the result.

Blocking. A chemical occupies the receptor without activating it, so the real hormone cannot land, and the body fails to respond to a signal it is genuinely sending.

Changing the supply chain. A chemical leaves receptors alone and interferes with how the hormone is produced, transported or broken down, such as by altering liver metabolism. NIEHS also says plainly that for some of these chemicals, nobody is certain how they act.

Now the definition, because that is where confusion starts. The 2017 consensus group worked from a definition it attributes to the World Health Organization, and which the European Parliament endorsed in a 2013 resolution. An endocrine disruptor is an outside substance or mixture that changes how the endocrine system works and, as a consequence, causes adverse effects in an intact organism, in its offspring, or in populations.

Read that slowly. It contains two tests, not one. Does the substance alter endocrine function, and does that alteration cause harm? Both terms are technical. An adverse effect means a change in form, function, growth, reproduction, development or lifespan that impairs functional capacity or the ability to handle other stresses. An intact organism means the effect must show up in something living, whether a test animal, patients, population data, or a validated alternative test that predicts those outcomes.

A chemical can satisfy the first test and fail the second. That gap is where the marketing lives.

Timing is doing more work here than dose

In most of toxicology the question is how much. Here, when can matter more.

Hormones do not only run the body minute to minute. During development they program it, setting up tissues and systems that then operate for decades. The 2017 consensus group concluded that disrupting that programming role before and after birth can cause adverse effects that do not become evident until much later in life, so identifying an endocrine hazard has to account for when exposure happened relative to life stage. NIEHS adds that some effects appear to persist across more than one generation.

The clearest human example is also the oldest. Diethylstilbestrol, usually called DES, was a synthetic estrogen prescribed to pregnant women in the United States from 1940 to 1971 to prevent miscarriage and premature labor. It did not work for that. The National Cancer Institute estimates 5 to 10 million Americans were exposed, counting both the women who took it and the children exposed before birth. In 1971 researchers connected prenatal exposure to clear cell adenocarcinoma of the vagina and cervix in a small group of young women, and FDA advised physicians to stop prescribing it in pregnancy.

Two numbers from NCI’s fact sheet belong in one sentence. The risk of that cancer in exposed daughters runs about 40 times the unexposed rate, and it remains rare, at roughly 1 in 1,000 exposed daughters. Precancerous cervical changes and pregnancy complications are also more common, while findings in exposed sons are mixed.

What DES demonstrates is narrower and more useful than a general claim that chemicals cause cancer. The same drug at the same dose produced one set of consequences in the woman who swallowed it and a different set in the fetus she was carrying, and the consequence in the daughters stayed invisible for about twenty years. That is what a developmental window means, and it is why this field treats pregnancy, infancy and puberty as separate questions rather than as special cases of the adult question.

A 40-fold increase sitting on a rare outcome is still a rare outcome. Our article on reading health information covers that arithmetic generally, and our companion article on exposure applies it to chemicals.

If you are pregnant, planning a pregnancy, or working around chemicals, ask your own clinician or an occupational health service whether a specific exposure matters. They can weigh the actual substance, route and amount. A label cannot.

The argument at the center of the field

Regulatory toxicology rests on a few working assumptions. Response rises with dose. Testing high and extrapolating downward is therefore cautious. Somewhere there is a threshold below which nothing adverse happens, and the highest tested dose showing no adverse effect anchors a daily intake treated as safe. Our companion article on evaluating real-world exposure walks through that arithmetic.

Part of the endocrine literature reports results that do not fit that picture.

What one side holds. Effects turn up at doses below the no-effect level drawn from standard testing, and some dose-response curves are non-monotonic, meaning they do not rise steadily. A curve can bend, so a low dose produces an effect that a higher dose does not. Laura Vandenberg, then at the University of Massachusetts Amherst, counted this in the bisphenol A literature in a 2013 paper in Dose-Response, reporting non-monotonic responses in more than 20 percent of experiments and in at least one endpoint in more than 30 percent of the studies she examined. A 2018 commentary by Corinne Hill, J. P. Myers and Vandenberg argued such curves occur below the no-adverse-effect level and sometimes below reference doses already in regulatory use. If that is right, extrapolating downward is not cautious at all. The Endocrine Society, the professional body for hormone scientists and physicians, reached a related conclusion in Endocrine Reviews in 2015, finding the evidence strengthened while cautioning against inferring causality in humans.

What the other side holds. The objection is methodological rather than a denial that hormones act at low concentrations. In Regulatory Toxicology and Pharmacology in 2012, Lorenz Rhomberg and Julie Goodman, both at a consulting firm, replied to the low-dose case directly. Their criticisms: examples were offered without a systematic review of all pertinent data, statistical significance was read as evidence of causation and of harm, studies with positive results were not held to the standard applied to null ones, and it was not established that the doses were genuinely low and relevant to people. A separate strand, argued in Archives of Toxicology in 2021 by Andreas Natsch of a fragrance manufacturer, concerns replication across independent, blinded laboratories.

The dispute has had consequences outside journals, and the 2017 consensus statement records the sequence. In 2013 a group of toxicology journal editors published objections to the European Commission’s draft criteria for identifying these chemicals, and endocrinologists published replies. The Commission then missed its legal deadline of December 2013 to adopt criteria. Sweden took it to court in 2014, and in late 2015 the General Court of the European Union ruled the Commission had breached EU law.

In April 2016 Germany’s Federal Institute for Risk Assessment hosted a two-day meeting in Berlin that put scientists from both camps in one room. The shape of what they agreed, published the next year, is where this article’s argument comes from.

What they agreed: identifying a chemical as an endocrine disruptor is a hazard identification exercise, so disagreements about thresholds and non-monotonic curves, while genuinely relevant to assessing risk, do not have to be settled before identification criteria can be written.

What they did not agree: the thresholds and the non-monotonic curves. In their own assessment, a consensus on those questions is unlikely to emerge in the near future.

That was not the first attempt. A September 2012 workshop, summarized by Claire Beausoleil and colleagues in Chemosphere in 2013, brought laboratory scientists and risk assessors together specifically to weigh the low-dose evidence. No consensus was reached there either.

Why the experiment is so hard to run

The consensus group identified the crux. It may be impossible to tell a true threshold from an apparent one that exists only because the experiment could not detect anything smaller. On that reasoning the threshold question cannot be answered by dose-response studies alone. It needs mechanistic work on how developmental programming happens and better knowledge of the sensitive windows.

One serious attempt was made to settle a piece of it directly. The Consortium Linking Academic and Regulatory Insights on Bisphenol A Toxicity, shortened to CLARITY-BPA, paired a guideline-compliant two-year study at FDA’s National Center for Toxicological Research with hypothesis-driven work by academic investigators funded by NIEHS, using animals from the same colony under the same dosing regimen.

The published answers did not converge. The core study team, reporting in Food and Chemical Toxicology in 2019, used five dose levels from 2.5 to 25,000 micrograms per kilogram of body weight per day and found no consistent treatment-related effects, with a possible relationship only at the top dose. An academic team reporting in Environmental Health Perspectives in 2020 measured the developing mammary gland quantitatively, described non-monotonic effects, and noted that the core study had itself recorded a significant increase in mammary adenocarcinoma at the lowest dose tested in one arm. A 2019 review by Frederick vom Saal argued the design was tilted toward missing effects, citing the rat strain’s estrogen sensitivity and the daily gavage dosing.

Same animals, same doses, same program, different conclusions. What counts as an adverse effect, which endpoint gets measured and how the data get analyzed are judgments made before any data exist. The bisphenols get their own article here. What matters in this one is why the argument survived a study built to settle it.

The consensus group’s own research priorities say what settling it would take: mechanistic work on whether developmental programming effects are threshold-dependent, epidemiology that measures exposure during the windows that matter rather than years afterward, validated tests for modes of action that have none, and independent replication. None of that is quick.

“Free of endocrine disruptors” is a claim nobody defines

Every claim on a package is defined in regulation, run as a government certification program, certified by a private third party, or undefined. This one is undefined, for four separate reasons.

There is no agreed list to be free of. EPA runs the Endocrine Disruptor Screening Program, and its page on the subject, updated in August 2026, describes screening, testing and research programs, two published chemical lists, and an effort to rebuild the program around a prioritized list. Those lists name chemicals selected for examination, not chemicals found to disrupt anything.

A screening result is not a verdict. Vandenberg’s 2021 review of endocrine toxicity testing describes EPA’s battery as eleven first-tier and three second-tier assays, aimed at agonists and antagonists of the estrogen, androgen and thyroid hormone receptors and at chemicals interfering with steroid production. A first-tier hit means interaction was detected. It does not establish harm, and says nothing about dose.

No agency certifies absence. Take cosmetics. Apart from color additives, FDA says nothing in a cosmetic needs its approval before the product goes on sale, and no specific safety test is mandated for any single product or ingredient, by statute or by FDA’s own rules. Responsibility sits with the seller.

The one federal rule touching the claim is about deception, not chemistry. The Federal Trade Commission’s environmental marketing guides include a section on free-of claims. Misrepresenting that a product does not contain a substance is deceptive, and a literally true claim can still mislead in two situations: the product contains something posing the same or similar risks, or the substance was never associated with that product category in the first place. Trace amounts can still support the claim when the level is no higher than an acknowledged background level, its presence does not cause the harm consumers associate with the substance, and it was not added deliberately. A formaldehyde-free label on insulation emitting trace formaldehyde below ordinary outdoor levels is acceptable, by FTC’s own illustration; a chlorine-free bleaching claim on shirts that still release significant amounts of the same harmful byproducts is not.

So the claim is constrained only by whether it misleads, and the category it names has no agreed membership to measure it against.

None of this means the underlying science is empty. It means the label is not a summary of the science.

Endocrine active and hormone disrupting are not the same claim

The 2017 consensus group, which included scientists who had publicly disagreed with each other, agreed on this: “endocrine activity on its own should not trigger a chemical’s identification as an endocrine disruptor.”

That is the distinction most worth carrying away. Endocrine activity means interaction with the hormone system. Endocrine disruption adds harm as a result of that interaction. A cell assay that lights up has shown activity, and a toxicology paper calling a compound endocrine active is reporting that narrower thing on purpose.

The same group agreed that potency matters when characterizing a hazard but not when identifying one, and noted that above sufficiently high test doses, illustrated with an oral toxicity limit of 1,000 milligrams per kilogram of body weight per day, identification would not be warranted.

So even inside the technical definition, identification carries no dose. Neither phrase tells you how much is in the product, how much gets into a person, or whether that amount matters. Those are the three questions our companion article on exposure is built around.

Five questions for any endocrine claim

1. Is this about interaction or about harm? Which was measured?
2. At what dose and by what route? Fed to an animal, injected, or added to cells in a dish?
3. Was the exposure timed to a developmental window, and does that window apply to the person the claim is aimed at?
4. Who checked this product, against which list? If the honest answers are nobody and none, that is the answer.
5. What would I do differently if the claim were false? If nothing changes either way, it does not deserve the space it is taking up.

What to do with a claim you cannot verify

The two central phrases in this subject do different jobs. Endocrine disruptor names a category defined by mechanism plus harm, and the harm half is contested at low doses in ways working scientists do not expect to resolve soon. Free of endocrine disruptors names nothing in particular, because no list, test or certifier stands behind it. One phrase describes a scientific argument that is still running. The other describes a marketing decision. The confusion in this aisle comes from reading them as the same kind of statement.

For symptoms, go to a clinician rather than to an ingredient list. A change in menstrual cycles, difficulty conceiving after a year of trying, unexplained shifts in weight or tolerance of heat and cold, or signs of puberty in a child before age eight are all reasons to be seen, because hormone levels can be measured in blood and a thyroid or pituitary problem is far more common than any exposure a label could describe.

For an actual exposure, such as a swallowed product or a spill, call Poison Help at 1-800-222-1222, 24 hours a day. Call 911 if someone is unconscious or having trouble breathing.

Sources

1. National Institute of Environmental Health Sciences. “Endocrine Disruptors (fact sheet, March 2023).” niehs.nih.gov
2. U.S. Environmental Protection Agency. “Endocrine Disruption.” epa.gov
3. National Library of Medicine, MedlinePlus. “Hormones.” medlineplus.gov
4. National Library of Medicine, MedlinePlus. “Endocrine Diseases.” medlineplus.gov
5. National Cancer Institute. “Diethylstilbestrol (DES) Exposure and Cancer.” cancer.gov
6. Federal Trade Commission (Code of Federal Regulations, eCFR). “16 CFR 260.9, Free-of claims.” ecfr.gov
7. U.S. Food and Drug Administration. “FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated.” fda.gov
8. World Health Organization and United Nations Environment Programme. “State of the science of endocrine disrupting chemicals 2012.” who.int
9. PubMed. “Solecki R, et al. "Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement." Archives of Toxicology, 2017. DOI: 10.1007/s00204-016-1866-9.” doi.org
10. PubMed. “Vandenberg LN. "Non-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol A as a case study." Dose-Response, 2013. DOI: 10.2203/dose-response.13-020.Vandenberg.” doi.org
11. PubMed. “Hill CE, Myers JP, Vandenberg LN. "Nonmonotonic Dose-Response Curves Occur in Dose Ranges That Are Relevant to Regulatory Decision-Making." Dose-Response, 2018. DOI: 10.1177/1559325818798282.” doi.org
12. PubMed. “Rhomberg LR, Goodman JE. "Low-dose effects and nonmonotonic dose-responses of endocrine disrupting chemicals: has the case been made?" Regulatory Toxicology and Pharmacology, 2012. DOI: 10.1016/j.yrtph.2012.06.015.” doi.org
13. PubMed. “Natsch A. "Scientific discrepancies in European regulatory proposals on endocrine disruptors, REACH regulation quo vadis?" Archives of Toxicology, 2021. DOI: 10.1007/s00204-021-03152-7.” doi.org
14. PubMed. “Beausoleil C, et al. "Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary." Chemosphere, 2013. DOI: 10.1016/j.chemosphere.2013.06.043.” doi.org
15. PubMed. “Gore AC, et al. "EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals." Endocrine Reviews, 2015. DOI: 10.1210/er.2015-1010.” doi.org
16. PubMed. “Camacho L, et al. "A two-year toxicology study of bisphenol A (BPA) in Sprague-Dawley rats: CLARITY-BPA core study results." Food and Chemical Toxicology, 2019. DOI: 10.1016/j.fct.2019.110728.” doi.org
17. PubMed. “Montevil M, et al. "A Combined Morphometric and Statistical Approach to Assess Nonmonotonicity in the Developing Mammary Gland of Rats in the CLARITY-BPA Study." Environmental Health Perspectives, 2020. DOI: 10.1289/EHP6301.” doi.org
18. PubMed. “vom Saal FS. "Flaws in design, execution and interpretation limit CLARITY-BPA's value for risk assessments of bisphenol A." Basic & Clinical Pharmacology & Toxicology, 2019. DOI: 10.1111/bcpt.13195.” doi.org
19. PubMed. “Vandenberg LN. "Toxicity testing and endocrine disrupting chemicals." Advances in Pharmacology, 2021. DOI: 10.1016/bs.apha.2021.05.001.” doi.org